KIT and neoplasm: Data from studies on GISTs showing a substantial proportion contain a mutation in exon 11 leading to ligand-independent c-kit activation, have shown that treatment with STI571, an inhibitor of PDGFR, Bcr-Abl, and c-kit tyrosine phosphorylation, causes tumor regression (77).